Volume 2.03 | Jan 28

Prostate Cell News 2.03, January 28, 2011.
In this issue: Science News  |  Current Publications  |  Industry News  |  Policy News  |  Events Subscribe  |  Unsubscribe


IL-6 Promotes Prostate Tumorigenesis and Progression Through Autocrine Cross-Activation of Insulin-Like Type I Growth Factor Receptor 
Scientists now provide the first evidence that IL-6 can induce tumorigenic conversion and further progression to an invasive phenotype of non-tumorigenic benign prostate epithelial cells. [Oncogene]



Facebook Cell Therapy News is now on Facebook. Join us! 

Twitter Follow us on Twitter! @ProstateCell

Interested in recruiting talented individuals? Post your career opportunities in Prostate Cell News at no cost. Contact us at [email protected]


Wall Street Journal Reports on Rogosin’s Novel Cancer Macrobead Research
Researchers are taking tumor cells from mice, encapsulating them in agarose beads and implanting them in the abdomen of cancer patients. There, cells in the beads secrete proteins researchers believe could signal a patient’s cancer to stop growing, shrink or even die. [Press release from The Rogosin Institute discussing online prepublication in Cancer Research]

Watch Procedure Now  
Use ALDEFLUOR® to Detect Prostate Precursor Cells
by STEMCELL Technologies

CURRENT PUBLICATIONS (Ranked by Impact Factor of the Journal)


Hydrophilic Agarose Macrobead Cultures Select for Outgrowth of Carcinoma Cell Populations That Can Restrict Tumor Growth
Scientists describe a novel property of tumor growth regulation that is neither species nor tumor-type specific. [Cancer Res]

A Novel Synthetic Protoapigenone Analogue, WYC02-9, Induces DNA Damage and Apoptosis in DU145 Prostate Cancer Cells Through Generation of Reactive Oxygen Species
WYC02-9 was investigated for its cytotoxicity against DU145 prostate cancer cells as well as the underlying mechanisms by which WYC02-9 might induce DNA damage and apoptotic cell death through reactive oxygen species. [Free Radic Biol Med]

Expression of SLCO Transport Genes in Castration Resistant Prostate Cancer and Impact of Genetic Variation in SCLO1B3 and SLCO2B1 on Prostate Cancer Outcomes
Researchers evaluated SLCO gene expression in castration resistant prostate cancer metastases and determined whether prostate cancer outcomes are associated with single nucleotide polymorphisms in SLCO2B1 and SLCO1B3, transporters previously demonstrated to mediate androgen uptake. [Cancer Epidemiol Biomarkers Prev]

Effects of Androgen Receptor and Androgen on Gene Expression in Prostate Stromal Fibroblasts and Paracrine Signaling to Prostate Cancer Cells
Although investigators are broadly aware of the specifics of the genomic actions of androgen receptor (AR) in prostate cancer cells, relatively little is known regarding the gene targets of functional AR in prostate stromal cells. Here, investigators describe a novel human prostate stromal cell model that enabled them to study the effects of AR on gene expression in these cells. [PLoS One]

Human Prostate Cell Lines from Normal and Tumorigenic Epithelia Differ in the Pattern and Control of Choline Lipid Headgroups Released into the Medium on Stimulation of Protein Kinase C
Scientists studied whether the development of tumorigenesis in prostate epithelial cell lines modifies the normal pattern of choline metabolite release on protein kinase C activation. [Br J Cancer]

MicroRNA-100 Expression Is Independently Related to Biochemical Recurrence of Prostate Cancer
Researchers determined the correlation of miRNA expression profiles with prostate cancer progression. [J Urol]

Restoration of miR-145 Expression Suppresses Cell Proliferation, Migration and Invasion in Prostate Cancer by Targeting Fascin Homolog 1
Using the prostate cancer cell lines, PC3 and DU145, gain-of-function assays revealed that miR-145 transfection inhibited cell proliferation, migration and invasion. [Int J Oncol]

Expression of Leukemia/Lymphoma Related Factor (LRF/Pokemon) in Human Benign Prostate Hyperplasia and Prostate Cancer
In this study, the expression of LRF was evaluated in benign prostate hyperplastic and prostate cancer tissues. [Exp Mol Pathol]

Development of an MHC Class I Ld-Restricted PSA Peptide-Loaded Tetramer for Detection of PSA-Specific CD8+ T Cells in the Mouse
Scientists set out to develop a PSA peptide-loaded tetramer for enumeration of PSA-specific CD8+ T cells in the Balb/c mouse model. [Prostate Cancer Prostatic Dis]


Association of Obesity with Prostate Cancer: A Case-Control Study Within the Population-Based PSA Testing Phase of the ProtecT Study
Scientists used cases and stratum-matched controls from the population-based PSA-testing phase of the Prostate testing for cancer and Treatment (ProtecT) study to examine the hypothesis that obesity as measured by body mass index, waist circumference and waist-to-hip ratio is associated with increased prostate cancer risk, and with higher tumor stage and grade. [Br J Cancer]

A Population-Based Model to Describe Geometrical Uncertainties in Radiotherapy: Applied to Prostate Cases
This paper proposes a model based on the principal component analysis to describe the patient-specific local probability distributions of voxel motions so that the average values and variances of the dose distribution can be calculated and fully used later in inverse treatment planning. [Phys Med Biol]


First Patients Complete Proton Therapy Treatment at CDH Proton Center, A ProCure Center
Two months after the opening of the CDH Proton Center, A Procure Center, the first patients have “graduated” from their treatment surrounded by family, friends and staff. [ProCure CDH Proton Center Press Release]

GSK Receives FDA Complete Response Letter for Avodart for Prostate Cancer Risk Reduction Supplemental Indication
GlaxoSmithKline (GSK) announced that the Company has received a Complete Response letter from the U.S. Food and Drug Administration (FDA) for the supplemental New Drug Application for Avodart® (dutasteride) for reducing the risk of prostate cancer in men at increased risk for the disease, defined as those who have had a prior negative biopsy due to clinical concern and have an elevated serum prostate-specific antigen. [GlaxoSmithKline Press Release]

Nuclea Biotechnologies, Inc. and Boston Medical Center Announce Unique Partnership
Biomarker pioneer Nuclea Biotechnologies, Inc. announced a new partnership with Boston Medical Center that could lead to more effective treatments for people with breast and prostate cancers. [Nuclea Biotechnologies, Inc. Press Release]

Sunshine Biopharma and Binghamton University (State University of New York) Enter into Research Agreement
Sunshine Biopharma, Inc. announced that it has executed an agreement with The Research Foundation of the State University of New York, acting for and on behalf of Binghamton University. [Sunshine Biopharma, Inc. Press Release]

Uncovering the Genetics of Prostate Cancer
In a research network funded by the German Ministry of Research and Education with 7.5 million Euro, physicians and scientists are now planning to uncover the genetics of early prostate cancer. [EurekAlert!]


European CHMP Begins Review of Calcitonin-Containing Medicines
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has started its review examining the increased risk of prostate cancer progression and other types of malignancies in patients taking calcitonin-containing medicines for the prevention of acute bone loss. [The Committee for Medicinal Products for Human Use, United Kingdom]

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Learn more about Prostate Cell News: Archives  |  Events  |  Subscribe  |  Contact Us